Binding Site is a Specialist Protein company committed to the research, development, manufacture and distribution of innovative immunodiagnostic assays for the global laboratory market. With extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.
Binding Site Offices
The Binding Site Group Ltd, Birmingham, UK is the headquarters of Binding Site
employing over 390 people.
In addition to research activities, the main site houses all product development and manufacturing along with global distribution, marketing and administrative functions. Direct sales and product support to customers in the UK are based here together with sales and technical support provided to our distributor network in 81 countries .
Direct Binding Site sales and support organizations are also based in: San Diego, California for USA & Canada Schwetzingen, near Heidelberg for Germany & Austria Grenoble for France & French speaking distributor markets Barcelona for Spain Prague for Czech Republic & Slovak Republic Antwerp for Belgium, Netherlands & Luxembourg Bergamo, near Milan for Italy
Innovative Immunodiagnostic Assays from Binding Site Freelite®
is a novel and unique assay now being used increasingly
for the diagnosis and monitoring of Multiple Myeloma, a cancer of cells in the bone marrow. Freelite comprises two immunodiagnostic assays for accurate and rapid quantification of free kappa and free lambda immunoglobulin light chain concentrations in serum. These assays can be performed on a significant number of automated platforms giving a sensitivity, accessibility and consistency never before achievable. Freelite has allowed significant improvements in both laboratory and clinical practice for the detection and monitoring of B cell malignancies.
Immune Status including Primary Immunodeficiency Diseases (PID). Binding Site is a market leader in the development of products for the investigation of immune status including PID. Our current range of specialized products includes assays to measure specific antibody response to vaccination and assays to quantify immunoglobulins and subclasses in human serum. In addition, we have developed a range of products optimized for use in plasma screening during the manufacture of therapeutic immunoglobulin and hyperimmune products.
Optimized Instrumentation and Assays
The SPAPLUS analyzer has been developed exclusively for Binding Site Special Protein Assays. Binding Site has harmonized assay and analyzer into a dedicated system to ensure optimal assay performance and throughput.
Reducing our Impact on the Environment
Binding Site's environmental policy outlines our commitment to limit the overall impact our processes have on the environment. The new 2011 head office was built with a focus on reduced energy and water consumption, has provisions for rainwater harvesting and meets strict carbon emission restrictions. All staff are trained on our Reduce, Reuse & Recycle policy.
Queen’s Award for Enterprise
Binding Site was awarded The Queen's Award for Enterprise 2010, in the category International Trade, for its outstanding achievement in increasing export revenues by 74% in 3 years and selling more than 90% of its production overseas. This is Binding Site’s 3rd Queen’s Award.
Our manufacturing site has quality systems approved to both ISO9001 and ISO13485:2003 certification. These, together with strict adherence to rigorous internal quality control procedures, ensure customers can be confident in the quality of Binding Site products.
Assays for in vitro diagnostic use have been FDA cleared for the USA and CE marked for Europe. Performance of our assays is regularly monitored by participation in a number of independent national and international quality assurance schemes.
More information at: www.thebindingsite.com
Contact your local office
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24